



Bank of America Merrill Lynch 2018 Energy Credit Conference

JUNE 6, 2018



Forward-Looking Statements

This Presentation has been prepared by Calumet Specialty Products Partners, L.P. (the "Company" or "Calumet") as of June 6, 2018. The information in this Presentation includes certain "forward-looking statements." These statements can be identified by the use of forward-looking terminology including "may," "intend," "believe," "expect," "anticipate," "estimate," "forecast," "continue" or other similar words. The statements discussed in this Presentation that are not purely historical data are forward-looking statements. These forward-looking statements discuss future expectations or state other "forward-looking" information and involved risks and uncertainties. When considering forward-looking statements, you should keep in mind the risk factors and other cautionary statements included in our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q could cause our actual results to differ materially from those contained in any forward-looking statement.

Our forward-looking statements are not guarantees of future performance, and actual results and future performance may differ materially from those suggested in any forward-looking statement. All subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the foregoing. Existing and prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this Presentation. We undertake no obligation to publicly release the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this Presentation or to reflect the occurrence of unanticipated events.

The information contained herein has been prepared to assist interested parties in making their own evaluation of the Company and does not purport to contain all of the information that an interested party may desire. In all cases, interested parties should conduct their own investigation and analysis of the Company, its assets, financial condition and prospects and of the data set forth in this Presentation. This Presentation shall not be deemed an indication of the state of affairs of the Company, or its businesses described herein, at any time after the date of this Presentation nor an indication that there has been no change in such matters since the date of this Presentation.

This Presentation and any other information which you may be given at the time of presentation, in whatever form, do not constitute or form part of any offer or invitation to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company, nor shall it or any part of it form the basis of, or be relied upon in connection with, any contract or commitment whatsoever. Neither this Presentation nor any information included herein should be construed as or constitute a part of a recommendation regarding the securities of the Company. Furthermore, no representation or warranty (express or implied) is made as to, and no reliance should be placed on, any information, including projections, estimates, targets and opinions contained herein, and no liability whatsoever is accepted as to any errors, omissions or misstatements contained herein. Neither the Company nor any of its officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this Presentation.





Calumet Investment Summary



Specialty Products Focus

High margin, high touch, tailored products for long-term customers



Turnaround Strategy Progressing Well

- Executed two non-core asset divestitures in 4Q17
- Redeemed 11.5% secured notes and renewed revolver
- Committed to further leverage reduction and balance sheet improvement



"Self-Help" Driving EBITDA Improvement

- Realigned organizational structure and rebuilt culture around P&L ownership and accountability
- Targeted cost reductions, raw materials optimization, margin enhancements, opportunistic growth projects and new product introductions



Investing In Our Future

- Recently launched state of the art Innovation Center
- Introduced new products (Group III Synthetic Base Oil & Uninhibited Transformer Oil)
- Expanded capacity to grow high margin Finished Lubricants & Specialty Chemicals division
- Complementing with opportunistic M&A (Biosynthetic Technologies, LLC closed Mar'18)



Calumet at a Glance

- NASDAQ: CLMT
- HQ: Indianapolis, IN
- Established 1919 New Leadership 2016/2017
- 11 manufacturing facilities in 6 states
- Production capacity ~140,000 bpd

FACILITY INFORMATION

SPECIALTY PRODUCTS AND FUELS REFINERIES

Shreveport, LA	60,000 bpd
2 Great Falls, MT	25,000 bpd
3 San Antonio, TX	21,000 bpd
Octton Valley, LA	13,500 bpd
9 Princeton, LA	10,000 bpd

SPECIALTY PRODUCTS PRODUCTION FACILITIES

Dickinson, TX	1,300 bpd
Karns City, PA	5,500 bpd
8 Louisiana, MO	200,000 lbs./day

BLENDING AND PACKAGING FACILITIES

- Porter, TX
- Tarmingdale, NJ
- Shreveport, LA

DISTRIBUTION TERMINALS

Burnham, IL	150,000 barrels
® Tooele, UT*	595,000 barrels

ADMINISTRATION AND SALES FACILITIES

- 1 Indianapolis, IN Corporate Headquarters
- Mexico City, MX
- 1 Houston, TX

RESEARCH AND DEVELOPMENT

Indianapolis, IN - The Product Innovation
 Center for Excellence



A leading independent producer of high-quality, specialty hydrocarbon products

^{*} Contracted Facility

Product Portfolio Supports The Things You Use Every Day

- Manufacturer of key components and solutions for numerous branded products that consumers use every day
 - Highly customized formulations
 - Stringent certifications, approvals and qualification requirements
 - Very strong and sticky/loyal customer base

















































NOTE: The above customer trademarks are the property of their respective owners.

Proud to partner with the world's best companies to help deliver some of the world's most trusted brands.

Our Transformation

2016: Reset

2017: Execute

2018 & Beyond: Transform

- Refocused operations on what Calumet does best creating premium, specialty products
 - Rationalized asset portfolio
 - Reduced exposure to commodity-oriented businesses
 - Initiated corporate culture change focused on cost and capital discipline
- Restructured specialty segment to focus on four product lines
 - Appointed dedicated general managers to drive P&L ownership and accountability
 - Supported by realigned sales teams, business development and analytical support
- Instituted three-year self-help program to realize \$150-\$200 million of additional EBITDA by 2019
- Refocused business on product innovation to grow EBITDA



Calumet is First and Foremost a Specialty Company

TTM ADJUSTED EBITDA BY SEGMENT^{1,2}

TTM SPECIALTY SALES BY PRODUCT 1,2







HIGHER VOLULME HIGHER MARGIN





Adjusted for 2017 asset divestitures

² Trailing Twelve Months ended March 31, 2018

³ Lubricating Oils = Paraffinic Base Oils + Naphthenic Base Oils + White Oils

Participating in Multiple Attractive End Markets

	Auto Aftermarket	Paints & Coatings	Pharma & Fine Chemicals	Dietary Supplements	U.S. Water Treatment	Industrial & Institutional Cleaning	Personal Care Chemicals
Large Global Addressable Markets ¹	\$650B	\$180B	\$80B	\$39B	\$13B	\$12B	\$8B
Attractive Growth Profiles	4-5%	5-6%	6%	5-6%	6%	4-5%	5-6%
Base Oils	✓					✓	
Solvents	✓	✓			√	✓	✓
White Oils & Petrolatums			✓	✓		✓	
Waxes		✓				✓	✓
Finished Lubricants & Chemicals	√					✓	





Our Strategy & Roadmap for Growth

OUR VISION

To be the premier specialty petroleum products company in the world.

OUR MISSION

We build high-return niche businesses through innovation, unmatched customer service and best-in-class operations to deliver quality products that meet the unique needs and specifications of our customers. We capture attractive opportunities where others do not.

Strategic

M&A

Focus portfolio on high-return,
niche specialty markets where
we are competitively advantaged

Opportunistic Growth Projects

 Capture one-to-two-year payouts with low capital investment requirements

Operations Excellence

 Reduce costs, optimize raw materials and enhance margins





Specialty Segment: Overview



Paraffinic lubricating oils, waxes



Naphthenic lubricating oils



Aliphatic solvents



White mineral oils, natural petroleum sulfonates, compressor lubricants



Louisiana, Missouri

Polyolester based synthetic lubricants



Petrolatums, white oils, solvents, gels



Synthetic industrial lubricating oils, gear oils



Farmingdale, New Jersey

Synthetic, industrial and commercial lubricating oils




San Antonio, Texas

Solvents

Specialty Segment Provides Stable EBITDA Margins

- Base business of ~\$200 million annually and growing
- Seasonally strongest during Q1 & Q2
- Directional trend in crude oil prices (primary feedstock) impacts quarterly margins
- Pricing adjustments typically have 8-12 week lag time
- Margins average ~15% on a TTM basis, showing significant stability across the context of the full-year







Finished Lubricants & Chemicals Opportunity

- Consumer-facing branded products
- Commands premium pricing
- Significantly higher EBITDA margins
- Growth focused opportunities
 - Expanding into previously untapped markets (e.g. Royal Purple into industrial applications)
 - Recent expansions to production capacity for TruFuel and Royal Purple
 - Introduced several new products in 2017 (Group III
 Synthetic Base Oil & Uninhibited Transformer Oil)













Fuels Segment: Cost-Advantaged Crude Opportunities

- Three facilities: One pure-play fuels refinery & two integrated facilities (specialty chemicals and fuels products)
- Seasonally strongest in Q2 & Q3 (summer driving season)
- Focused on capturing cost-advantaged crude opportunities
 - Heavy Canadian: Processing ~25,000 bpd of WCS-priced crudes
 - Permian: Processing ~7,000 bpd of Midland-WTI priced crudes and targeting 17,000 bpd in 2H18



Shreveport, Louisiana

- Capacity: 60,000 bpd
- Specialty & Fuels facility
- Lower utilization rates as primary Specialty facility in system



Great Falls, Montana

- Capacity: 25,000 bpd
- Fuels refinery
- Runs up to 100% cost-advantaged WCS-priced crudes



- Capacity: 21,000 bpd
- Historically Fuels focused, becoming more integrated as Specialty segment grows

Self-Help in Action: Delivering Results

- Delivered \$8.3 million in "self-help" during 1Q18, driven by:
 - Crude sourcing and inbound logistics
 - New product introductions and product upgrades
 - Supply chain efficiencies
- Surpassed low end of original program target goal of \$150-200 million
- Expecting to capture \$40-\$50 million of "self-help" in FY'18
 - Opportunistic growth projects
 - New Isomerate unit at San Antonio
 - Naphtha upgrade project at Great Falls
 - Continued growth expected in Finished Lubricants & Chemicals
 - Additional raw material and supply chain initiatives, many driven by new ERP system







Committed to Continued Balance Sheet Improvement

- Recent S&P upgrade to B- from CCC+
- Credit metrics remain strong
- Committed to long-term deleveraging


LIQUIDITY AVAILABILITY (\$MM)



NET DEBT TO LTM ADJUSTED EBITDA (LEVERAGE) RATIO




FIXED CHARGE COVERAGE RATIO (1)




CLMT NASDAQ LISTED

Multiple Expansion Opportunity

EBITDA Margin (2018E)



EV/EBITDA (2018E)



Source Data: Capital IQ, as of 5/30/2018. Calumet EV pro-forma to reflect redemption of senior secured notes.



Specialty Chemicals consists of EMN, FPE3, HUN, NGVT, IPHS, IOSP, KOP, NEU, NXEO, and KWR. Finished / Branded Products consists of CBT, CSWI, ECL, ITW, KMG, KRA, OMN, VVV, and WDFC.





Calumet Investment Summary



Specialty Products Focus

High margin, high touch, tailored products for long-term customers



Turnaround Strategy Progressing Well

- Executed two non-core asset divestitures in 4Q17
- Redeemed 11.5% secured notes and renewed revolver
- Committed to further leverage reduction and balance sheet improvement



"Self-Help" Driving EBITDA Improvement

- Realigned organizational structure and rebuilt culture around P&L ownership and accountability
- Targeted cost reductions, raw materials optimization, margin enhancements, opportunistic growth projects and new product introductions



Investing In Our Future

- Recently launched state of the art Innovation Center
- Introduced new products (Group III Synthetic Base Oil & Uninhibited Transformer Oil)
- Expanded capacity to grow high margin Finished Lubricants & Specialty Chemicals division
- Complementing with opportunistic M&A (Biosynthetic Technologies, LLC closed Mar'18)



APPENDIX

Supplemental Financial Data



EXHIBIT A: Biosynthetic Technologies: Overview



- Proprietary technology converts renewable plant oils into high-performance specialty products
 - Exceptional qualities for high performance synthetic lubricants
 - Extremely rigorous environmental specifications



- Industrial proof-of-concept at commercial scale to be conducted at Calumet's existing esters plant in Missouri
- Diverse specialty product applications under development at our New Product Innovation Center
- Calumet and The Heritage Group are actively exploring third party commercial participation

Biosynthetic Technologies: Opportunity



- Products deliver exceptional technical performance:
 - Increased oil longevity and low evaporation rates, while maintaining safety and high viscosity index in high temperature environments
- Also meets stringent environmental specifications for biodegradability, bioaccumulation and toxicity

Market/Product Applications & Total Addressable Market (1)

Automotive Industrial Marine **Personal Care** Process Oil Passenger Car Motor Oil Hydraulic Cosmetics Hvdraulic Oil Truck Engine Oil Grease **Emollients** Compressor Fluid Scooter / Motorcycle Oil Other Products Gear Oil Grease Transmission Fluid Trunk Piston Oil Metalworking Fluid Gear Oil; Grease Cylinder Oil \$87.1B \$64.5B \$13.1B \$12.0B





Biosynthetic Technologies: Robust IP Portfolio



Oleic-based Estolide molecules

Non-oleic based Estolide molecules

Catalysts for Estolide synthesis

Continuous and semi-continuous Estolide production process

By-products from Estolide synthesis

Varying Estolide viscosity grades

Estolide end product formulations

Estolide end product applications

- BT Patents: 71 issued patents
 - 54 issued U.S. patents
 - 17 issued Int'l patents
 - 22 pending U.S. patent applications
 - 54 pending Int'l applications
 - None expire before 2032
- Exclusive licensee of 2 original estolide patents from USDA
- Patent portfolio creates a broad and deep barrier to entry, protecting the company and our customers
- BT continues to file patent applications to extend its
 IP ownership in the bio-based synthetic oils sector
- All IP now owned exclusively by Calumet and The Heritage Group





Exhibit B: Historical Adjusted EBITDA by Segment (\$MM)









Exhibit C: Adjusted EBITDA Bridge – 1Q17 vs. 1Q18 (\$MM)





Includes mark-to-market, LCM, acquisition costs, hedging activities, and Superior Renewable Identification Numbers ("RINs") exemption.

⁽²⁾ Includes RINs costs.

Exhibit D: Cash Bridge – 4Q17 vs. 1Q18 (\$MM)







Exhibit E: Historical and Projected Capital Spending (\$MM)



(1) Includes \$36 million of contributions to DPR and \$29 million of proceeds related to the sale of unconsolidated affiliates






Exhibit F: Hedged a Portion of Anticipated 2019 WCS Purchases & 2019 Diesel Sales

Average WCS % of WTI: 65.25%

Average Diesel Crack % of WTI: 137.28%






EXHIBIT G: Capital Structure Overview

		Actual		Actual		Actual		Actual	Actual			Actual	l Actual		Actual	
(\$ in millions)	6/30/16		9/30/16		12/31/16			3/31/17	6/30/17			9/30/17	12/31/17		3/31/18	
Cash	\$	\$ 32.2		17.8	\$	4.2	\$	4.6	\$ 26.6		\$	26.5	\$	514.3	\$	496.6
ABL Revolver Borrowings	\$	0.1	\$	0.1	\$	10.2	\$	39.2	\$	0.4	\$	0.1	\$	0.2	\$	-
7.625% Senior Notes due 2022	\$	350.0	\$	350.0	\$	350.0	\$	350.0	\$	350.0	\$	350.0	\$	350.0	\$	350.0
6.50% Senior Notes due 2021	\$	900.0	\$	900.0	\$	900.0	\$	900.0	\$	900.0	\$	900.0	\$	900.0	\$	900.0
7.75% Senior Notes due 2023	\$	325.0	\$	325.0	\$	325.0	\$	325.0	\$	325.0	\$	325.0	\$	325.0	\$	325.0
11.50% Senior Secured Notes due 2021	\$	400.0	\$	400.0	\$	400.0	\$	400.0	\$	400.0	\$	400.0	\$	400.0	\$	400.0
Note Payable - related party	\$	40.7	\$	19.6	\$	-	\$	-	\$	-	\$	-	\$	-	\$	-
Capital Leases	\$	45.6	\$	47.5	\$	46.5	\$	45.9	\$	45.2	\$	44.7	\$	44.0	\$	43.7
Other	\$	-	\$	4.6	\$	8.0	\$	7.6	\$	7.3	\$	6.9	\$	6.6	\$	6.3
Total Debt	\$	2,061.4	\$	2,046.8	\$	2,039.7	\$	2,067.7	\$	2,027.9	\$	2,026.7	\$	2,025.8	\$	2,025.0
Partners' Capital	\$	331.5	\$	294.2	\$	218.7	\$	213.3	\$	224.0	\$	201.6	\$	119.9	\$	115.4
Total Capitalization	\$	2,392.9	\$	2,341.0	\$	2, 258.4	2, 258.4 \$		\$	2,251.9	51.9 \$ 2,228.		\$	2,145.7	\$	2,140.4
LTM Adjusted EBITDA (as reported)	\$	114.4	\$	92.9	\$	158.2	\$	230.3	\$	261.9	\$	303.7	'\$	317.2	\$	313.5
Net Debt / LTM Adjusted EBITDA (as reported)		17.7 x		21.8 x		12.9 x		9.0 x	7.6 x		6.6 >		(4.8 x			4.9 x
Net Debt / Total Capitalization		85%		87%		90%		90%		89%		90%	93%			93%





EXHIBIT H: Reconciliation of Segment Adjusted EBITDA to Net Income (Loss)

	12	/31/15	3/31/16	6/	30/16	9/30	0/16	12/	31/16	3/3	31/17	6/30	/17	9/3	0/17	12/3	1/17	3/31	/18
(\$ in millions)																			
Segment Adjusted EBITDA																			
Specialty products Adjusted EBITDA	\$	29.3 \$	58.5	\$	59.0	\$	43.4	\$	28.0	\$	45.6	\$	67.1	\$	43.0	\$	30.8	\$	37.7
Fuel products Adjusted EBITDA		(59.8)	(46.0)		18.9		13.8		3.2		36.8		34.0		46.3		10.7		38.7
Discontinued operations Adjusted EBITDA		(7.1)	(5.9)		(7.9)		(3.3)		(3.5)		(3.7)		0.5		6.4		(0.3)		(1.4)
Total segment Adjusted EBITDA Less:	\$	(37.6)	6.6	\$	70.0	\$	53.9	\$	27.7	\$	78.7	\$	101.6	\$	95.7	\$	41.2	\$	75.0
Unrealized (gain) loss on derivative Instruments Realized gain (loss) on derivatives, not included in net income (loss) or settled in	\$	11.8	\$ (4.6)	\$	(23.8)	\$	4.9	\$	3.6	\$	(10.6)	\$	(1.3)	\$	-	\$	(1.4)	\$	(2.0)
a prior period		(1.6)	(2.1)		(2.3)		(4.8)		2.8		-		-		9.7		-		-
Amortization of turnaround costs		9.6	9.1		8.3		7.9		8.0		7.4		6.6		6.4		3.9		3.3
Debt extinguishment costs		-	-		-		-		-		-		-		-		-		0.6
(Gain) loss on the sale of businesses, net		-	-		-		-		-		-		-		-		(173.4)		-
Impairment charges		-	-		33.4		-		2.5		0.4		-		-		206.9		-
Loss on sale of unconsolidated affiliate Non-cash equity based compensation and		-	-		113.9		-		-		-		-		-		-		-
other non-cash items		3.0	2.6		1.5		(2.2)		3.1		2.8		2.2		7.3		3.6		3.2
EBITDA	\$	(60.4) \$	1.6	\$	(61.0)	\$	48.1	\$	7.8	\$	78.7	\$	94.1	\$	72.3	\$	1.6	\$	69.9
Less:																			
Interest expense	\$	25.0 \$	30.3	\$	42.8	\$	44.6	\$	44.0	\$	43.9	\$	44.5	\$	47.4	\$	47.3	\$	45.2
Depreciation and amortization		38.0	38.8		43.8		44.5		44.0		41.1		40.9		48.6		37.9		29.7
Income tax expense (benefit)		(6.6)	0.2		0.3		(7.6)		(0.6)		(0.1)		(0.9)		(0.1)		-		(0.2)
Net income (loss)	<u>\$</u>	(116.8) \$	(67.7)	\$	(147.9)	\$	(33.4)	\$	(79.6)	\$	(6.2)	\$	9.6	\$	(23.6)	\$	(83.6)	\$	(4.8)

CONTACT INFORMATION

Joe Caminiti or Chris Hodges

Alpha IR

312-445-2870

Email: CLMT@alpha-ir.com



